NCT00852618|Completed
Loading search results
Sponsor study identifier
Secondary identifiers
REGISTRY · DAIDS ES
observational
11
1 country
6
Study Start
May 2008
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
September 2008
Actual (reported)The HIV integrase inhibitor, raltegravir (RAL), which was recently approved by the FDA, has been shown in several trials to be highly effective. The main study will estimate the viral load decay rate in treatment-naive HIV-infected participants receiving RAL and emtricitabine/tenofovir disoproxil fumarate (FTC/TDF). This substudy of A5248 will similarly examine the characteristics of decrease in viral load but will focus on estimating the time at which first-phase viral decay starts, following initiation of the study drugs.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2008
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2008
Date type not reportedThis date has not been verified as actual or estimated.
September 2008
Actual (reported)February 26, 2009
Actual (reported)February 27, 2009
Actual (reported)Time at which first-phase viral decay begins
Throughout study
Participants undergoing treatment with raltegravir (RAL) in the main study
Participants undergoing treatment with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in the main study
HIV-infected participants currently enrolled in study A5248
University of Colorado Hospital CRS
Aurora, Colorado, 80045, United States
IHV Baltimore Treatment CRS
Baltimore, Maryland, 21201, United States
Johns Hopkins University CRS
Baltimore, Maryland, 21205, United States
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS
Boston, Massachusetts, 02115, United States
Trillium Health ACTG CRS
Rochester, New York, 14607, United States
Vanderbilt Therapeutics (VT) CRS
Nashville, Tennessee, 37204, United States
Plasma samples will be collected throughout the study
Adriana Andrade, MD, MPH
Johns Hopkins University
11 participants (actual enrollment reported by the registry).
First Submitted
February 26, 2009
First Posted
February 27, 2009
Study Start
May 2008
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Study Completion
September 2008
Actual (reported)Last Updated
November 1, 2021
Record last verified: 2021-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: